Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AngioDynamics ( (ANGO) ) has shared an announcement.
AngioDynamics reported strong financial results for the fourth quarter and fiscal year 2025, ending May 31, 2025, with significant growth in MedTech sales and operational efficiency leading to positive adjusted EBITDA and free cash flow. The company achieved key regulatory milestones, expanded into new geographies, and secured critical reimbursement pathways, positioning itself for sustained growth and value creation in the global MedTech market.
The most recent analyst rating on (ANGO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.
Spark’s Take on ANGO Stock
According to Spark, TipRanks’ AI Analyst, ANGO is a Neutral.
AngioDynamics faces financial challenges with declining revenues and negative cash flows. However, strong earnings call performance, increased guidance, and strategic corporate events indicate potential for future growth. Valuation remains a concern due to negative earnings and no dividend yield.
To see Spark’s full report on ANGO stock, click here.
More about AngioDynamics
AngioDynamics, Inc. is a leading medical technology company focused on restoring healthy blood flow in the vascular system, expanding cancer treatment options, and improving the quality of life for patients. The company operates in the MedTech industry, with a market focus on cardiology and interventional oncology, offering innovative platform technologies.
Average Trading Volume: 518,935
Technical Sentiment Signal: Sell
Current Market Cap: $378.5M
Learn more about ANGO stock on TipRanks’ Stock Analysis page.